Sector ratings Biogen Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 11:55:12 2024-09-18 am EDT			5-day change	1st Jan Change
197.40 ^USD	-0.41%		-0.55%	-23.49%

Sep. 17	Biogen New Drug Submission for Friedreich's Ataxia Treatment Accepted for Priority Review in Canada	MT
Sep. 17	INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints	CI

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	ESG Refinitiv	Capi. ($)
BIOGEN INC.		B-	28.87B
CSL LIMITED		A-	96.83B
SAMSUNG BIOLOGICS CO.,LTD.		A-	53.25B
UCB		A	33.5B
BIOMARIN PHARMACEUTICAL INC.		C	13.43B
ALTEOGEN INC.		D	12.83B
INCYTE CORPORATION		B-	12.79B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.		D+	12.12B
SWEDISH ORPHAN BIOVITRUM AB		B+	11.18B
INNOVENT BIOLOGICS, INC.		B-	9.17B
INTRA-CELLULAR THERAPIES, INC.	-	D+	7.94B
GRIFOLS, S.A.		A-	7.19B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.		B	6.98B
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.		C-	6.11B
BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.		C	5.86B
BRIDGEBIO PHARMA, INC.	-	C-	5.03B
AVIDITY BIOSCIENCES, INC.	-	D	4.94B
AXSOME THERAPEUTICS, INC.	-	D	4.37B
ADMA BIOLOGICS, INC.	-	D+	4.36B
APELLIS PHARMACEUTICALS, INC.	-	C-	4.33B
Average		C+	17.05B
Weighted average by Cap.		C+